Kazia Therapeutics Limited (KZIA) NASDAQ
12.25
-0.31(-2.47%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.25
-0.31(-2.47%)
Currency In USD
Address
Three International Towers
Sydney, NSW 2000
Australia
Phone
1300 787 272
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
January 06, 1999
| Name | Title | Pay | Year Born |
| John Edwin Friend | Chief Executive Officer | 659,500 | 1970 |
| Elissa C. Hansen ACSA FCIS GAIC | Company Secretary | 34,502 | 1973 |
| Jeffrey Bonacorda | Vice President of Finance & Controller | 280,104 | N/A |
| Sudha Rao | Chief Scientific Officer | 0 | N/A |
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.